Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Risperidone and haloperidol are both antipsychotic medications. Risperidone is a benzisoxazole derivative, while haloperidol is a butyrophenone. Both are primarily dopamine receptor antagonists, with risperidone also acting as a serotonin 5-HT2A receptor antagonist. They are widely used in the treatment of psychiatric conditions such as schizophrenia and manic episodes associated with bipolar disorder. Clinical trials have also investigated their use in delirium, though some studies suggest they may not be more effective than placebo for this indication and can be associated with significant side effects like hyperprolactinemia and extrapyramidal symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on risperidone + haloperidol.